In response to our rapidly growing medical device contract manufacturing business, we are proud to announce the completion of our new state-of-the-art facilities in Dongguan, China.

Through this expansion, we have more than doubled the size of our plant, and our new 125,000 square foot facility will permit us to streamline our tooling, molding, and medical device assembly operations while leaving significant room for future contract manufacturing growth. Now fully operational, the new facilities feature product development and in-house tool building services, scientific injection molding capabilities to ensure device standardization, and both automated and manual assembly services. We plan to enhance our Asia manufacturing capabilities with Liquid Silicone Rubber (LSR) injection molding, as well as customer product development support with increased prototyping, bridge tooling, mold sampling, and short-run production. 

With the expansion of our facilities in China, we can provide our customers with the option to commercialize a project domestically in the United States or in a low-cost country (LCCS ), delivering a flexible yet cost-effective manufacturing alternative that many companies cannot offer. “This has allowed us to become a natural extension of our customers’ production capabilities by providing them with a reliable and proven partner to confidently develop and manufacture their finished medical devices across the globe,” said Brenan Riehl, President and CEO.

To learn more about this expansion or our capabilities in China, please contact Ben Bouchard, VP International Business Development and Managing Director – China, or visit our website.